← All candidates
One insider buy in the last year — $4.80M in all.
88 filings on record.
BCAXBicara Therapeutics Inc.
NasdaqGM · Healthcare · $1.48B
$22.00
-2.96% today
One insider buy in the last year — $4.80M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy● 48 sells◆ 5 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.48B
Float
36.9M
56% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
Ra Capital Management, L.p.
Bought $4.80M on Feb 26 — 300,000 sh @ $16.00, held indirect, 6.5% of their stake.
4 of 8 positions beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
83 more transactions on Pro →Context
Wall St
$31.46 avg target
+43.0% vs today · 13 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 4 quarters beat
Q1 '26−$0.93 act−$0.28
Q4 '25−$0.68 act−$0.03
Q3 '25−$0.67 act−$0.14
Q2 '25−$0.50 act+$0.04
Coverage
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?Motley Fool · 06-13Bicara (BCAX) Q4 2025 Earnings TranscriptMotley Fool · 06-01Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck CancerMarketBeat · 05-22A Look At Bicara Therapeutics (BCAX) Valuation After Recent Share Price Pullback
The file stays open
88 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice